Avagenesis and Avapecia Announce Collaboration Agreement


Calgary, Alberta and Richmond, British Columbia – Avagenesis Corp. (TSXV: VVA) and Avapecia Life Sciences Corp. (CSE: VVS) (“Company” or the “Companies”) are pleased to announce a Global Collaboration Agreement (“Agreement”) for Co-Distribution and Co-Marketing.

The Agreement ensures a standardized adipose stem cell therapy isolation and enrichment platform that produces a highly potent regenerative biopharmaceutical stem cell product at the point-of-care for a multitude of indications and conditions that have significant potential for use in stem cell therapies.

Subscribe to get the latest news